Get the Stockscreener App
10.99
4.91%
-0.5286
Keros Therapeutics Inc stock is traded at $10.99, with a volume of 622.25K.
It is down -4.91% in the last 24 hours and down -30.87% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$11.52
Open:
$11.44
24h Volume:
622.25K
Relative Volume:
0.44
Market Cap:
$466.44M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.1416
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
-3.95%
1M Performance:
-30.87%
6M Performance:
-75.88%
1Y Performance:
-78.70%
1-Day Range:
$10.95
$11.64
1-Week Range:
$10.95
$12.05
52-Week Range:
$9.775
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
10.97 | 466.44M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.48 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.61 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
KROS Shares Experience Surge in Value - Knox Daily
SG Americas Securities LLC Buys Shares of 24,493 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Examining Keros Therapeutics Inc (KROS) stock is warranted - US Post News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cantor Fitzgerald Downgrades Keros Therapeutics Inc (KROS) to a Neutral from an Overweight - Knox Daily
An analyst sees good growth prospects for Keros Therapeutics Inc (KROS) - SETE News
SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Exchange Traded Concepts LLC Makes New $99,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation - Markets Insider
KROS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Keros Therapeutics, Inc. and Encourages Investors to Contact the Firm - ACCESS Newswire
When (KROS) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation - Markets Insider
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Assenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Assenagon Asset Management S.A. Sells 158,767 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on ... - The Bakersfield Californian
Keros Therapeutics seals $200M deal with Takeda - MSN
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN
Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Cantor Fitzgerald - Defense World
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS) - Business Wire
Keros Therapeutics seals $200M deal with Takeda By Investing.com - Investing.com Australia
Cantor Fitzgerald Estimates KROS FY2025 Earnings - MarketBeat
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - GlobeNewswire
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Cantor Fitzgerald Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics stock rating cut to Neutral, cites dosing setback - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc.KROS - PR Newswire
Keros spikes as Teva deal takes effect; Cantor downgrades on trial setback - MSN
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros stock spikes as Teva deal takes effect (KROS:NASDAQ) - Seeking Alpha
Keros stock climbs on Takeda deal effectiveness - MSN
Keros Therapeutics (NASDAQ:KROS) Lowered to Neutral Rating by Cantor Fitzgerald - MarketBeat
Keros Therapeutics stock rating cut to Neutral, cites dosing setback By Investing.com - Investing.com Canada
Keros Therapeutics Secures $200M Upfront Payment in Major Takeda Licensing Deal for Elritercept - StockTitan
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):